India Amends Drugs Rules to Bring Cell and Gene Therapies Under Centralized Regulatory Oversight
核心洞察
The Indian government has amended the Drugs Rules, 1945, to place cell and gene therapy products under the Centrally License Approving Authority (CLAA) framework for joint central-state regulatory oversight.
The amendment covers stem cell-derived products, CAR-T cell therapies, gene therapeutic products including gene editing treatments, and xenografts such as animal-derived heart valves.
These highly complex and rapidly evolving technologies require enhanced regulatory scrutiny to ensure patient safety and uniformity in standards across the country.
The Indian government has amended the Drugs Rules, 1945, to bring a range of advanced medical technologies—including cell and stem cell-derived products, gene therapeutic products, and xenografts—under the Centrally License Approving Authority (CLAA) framework, marking a significant strengthening of the country's regulatory oversight for emerging therapies.
The amendment, announced by the Ministry on Thursday, July 2, 2026, expands the existing joint regulatory supervision model that currently covers vaccines, large volume parenterals (IV solutions exceeding 100 ml), and r-DNA based medicines under the Drugs and Cosmetics Act.
Scope of the Amendment
The newly covered product categories span some of the most innovative and rapidly advancing areas of modern medicine. Cell or stem cell-derived products, including stem cell-based regenerative treatments and CAR-T cell therapies, have seen increasing use in the treatment of blood cancers such as leukemias (搜索) and lymphomas (搜索). Gene therapeutic products—encompassing gene replacement and gene-editing products—have found application in treating genetic disorders (搜索) and various types of cancers. Xenografts, defined as animal tissue-derived products such as heart valves that can be transplanted into humans, are also included, with established uses in cardiology and orthopedics.
Regulatory Rationale
According to the Ministry, these technologies "represent highly complex, specialised and rapidly evolving areas of medical science" and consequently "need enhanced regulatory scrutiny to ensure patient safety." The inclusion under the CLAA framework facilitates a system of joint oversight by the Central and State Licensing Authorities, ensuring uniformity in regulatory standards across the country.
"The amendment will increase regulatory rigour for emerging technologies and reinforcing India's regulatory framework in line with scientific advancements and global best practices," the Ministry stated.
Implications for Innovation and Public Health
The regulatory update reflects a dual objective: safeguarding public health while fostering innovation. A government official noted that "this initiative reflects the government's continued commitment towards safeguarding public health while promoting innovation and quicker adoption of the latest technologies in healthcare and life sciences sectors."
By centralizing the approval pathway for these advanced therapies, the amendment aims to streamline regulatory processes while maintaining rigorous safety oversight—a balance critical for the continued development and accessibility of cutting-edge treatments in India.